NOAC Therapy Guided by PARIS Risk Score and D-dimer in Patients With ACS After PCI

The goal of this clinical trial is to compare short-term Triple Antithrombotic Therapy (DAPT + Rivaroxaban) followed by DAPT with standard DAPT in selected ACS patients with high ischemic risk. The main questions it aims to answer are: * Whether the intervention is effective in reducing ischemic events * Whether the intervention is safe from increasing bleeding events, especially severe or fatal ones Participants will be randomized to receive standard DAPT therapy for the entire study duration or low-dose rivaroxaban+DAPT for 3 months, followed by standard DAPT for the rest of the study duration. Patients enrolled should complete 5 follow-ups in the form of clinic visit or telephone call.

NCT Number	NCT05638867
Lead Sponsor	China National Center for Cardiovascular Diseases
Conditions	Coronary Artery Disease, Percutaneous Coronary Intervention, Acute Coronary Syndrome
Enrollment	3,944 participants
Start Date	2023-11-25
Primary Completion	2026-12 (estimated)
Study Completion	2027-01 (estimated)
Updated on ClinicalTrials.gov	2026-08-11